Dependence of Molecular Properties on Proteomic Family for Marketed Oral Drugs
- 13 May 2006
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 49 (12), 3451-3453
- https://doi.org/10.1021/jm0603825
Abstract
An association of drugs with their proteomic family reveals that molecular properties of drugs targeting proteases, lipid and peptide G-protein-coupled receptors (GPCRs), and nuclear hormone receptors significantly exceed limits for some properties in the “rule of five”, while drugs targeting cytochrome P450s, biogenic amine GPCRs, and transporters have significantly lower values for certain properties. Also, the variation in drug targets appears to be a factor explaining increasing molecular weight over time.Keywords
This publication has 17 references indexed in Scilit:
- Biospectra Analysis: Model Proteome Characterizations for Linking Molecular Structure and Biological ResponseJournal of Medicinal Chemistry, 2005
- Navigating chemical space for biology and medicineNature, 2004
- Characteristic Physical Properties and Structural Fragments of Marketed Oral DrugsJournal of Medicinal Chemistry, 2003
- A Comparison of Physiochemical Property Profiles of Development and Marketed Oral DrugsJournal of Medicinal Chemistry, 2003
- Selection criteria for drug‐like compoundsMedicinal Research Reviews, 2003
- Annotating the human proteome: the Human Proteome Survey Database (HumanPSDTM) and an in-depth target database for G protein-coupled receptors (GPCR-PDTM) from Incyte GenomicsNucleic Acids Research, 2002
- Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings 1PII of original article: S0169-409X(96)00423-1. The article was originally published in Advanced Drug Delivery Reviews 23 (1997) 3–25. 1Advanced Drug Delivery Reviews, 2001
- Computational methods for the prediction of ‘drug-likeness’Drug Discovery Today, 2000
- Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settingsAdvanced Drug Delivery Reviews, 1997
- A canonical structure for the ligand-binding domain of nuclear receptorsNature Structural & Molecular Biology, 1996